$OSCR Guidance 2026

$OSCR earnings: Q4 was a MISS but guidance was a HUGE BEAT Q4 results: ❌ Revenue: $2.81B (vs $3.1B est) ❌ EPS: -$1.24 (vs -$0.89 est) ❌ Medical Loss Ratio: 95.4% (very high) ✅ SG&A ratio: 18.2% (continued cost discipline) Strategic developments: ✅ Strong membership growth

$OSCR saw a 70% INCREASE IN MEMBERS to 3.4 MILLION. While others are crashing. While others are losing market share. While others are doubling down on failed Medicaid/medicare. Oscar is KILLING it in the ACA marketplace. INCREDIBLE GUIDANCE

I saw the $OSCR numbers come through this morning but the 2026 guidance was so far above consensus that I needed to double check on their IR page. It appears to be correct which means $OSCR initial CY2026 revenue guidance is ~50% above the current street estimates. Press

$PLTR Wild take. I think he’s right.

$OSCR „The time of maximum pessimism is the best time to buy, and the time of maximum optimism is the best time to sell.“ „To buy when others are despondently selling and to sell when others are greedily buying requires the greatest fortitude and pays the greatest reward.“ –

$OSCR 's real edge.

Raymond James upgrades Oscar Health $OSCR stock rating to Outperform - $18 PT investing.com/news/analyst-r…

$OSCR Oscar is using AI to decrease response times, and offer health related answers. As these tools improve, this provides long-term leverage over those who do not adapt. These decreased response times can be the difference between an Oscar or competitor plan. With 2026 member

$OSCR CEO on the Future of Healthcare